vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
Scinai Immunotherapeutics Ltd. is the larger business by last-quarter revenue ($773.0K vs $410.0K, roughly 1.9× Solowin Holdings, Ltd.).
AXG vs SCNI — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $773.0K |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | -34.1% | — |
| Net Margin | — | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $773.0K | ||
| Q3 24 | $410.0K | — | ||
| Q2 24 | — | $284.0K |
| Q2 25 | — | — | ||
| Q3 24 | -34.1% | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $7.9M |
| Total Assets | $13.1M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $989.0K | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | — | $3.1M |
| Q2 25 | — | $7.9M | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | — | $-7.3M |
| Q2 25 | — | $11.8M | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | — | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | — |
| Free Cash FlowOCF − Capex | $-1.6M | — |
| FCF MarginFCF / Revenue | -392.9% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | — |
| Q2 25 | — | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | — |
| Q2 25 | — | — | ||
| Q3 24 | -392.9% | — | ||
| Q2 24 | — | — |
| Q2 25 | — | — | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
